46 related articles for article (PubMed ID: 36170682)
1. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry.
García MJ; Rivero M; Fernández-Clotet A; de Francisco R; Sicilia B; Mesonero F; de Castro ML; Casanova MJ; Bertoletti F; García-Alonso FJ; López-García A; Vicente R; Calvet X; Barreiro-de Acosta M; Ferrer Rosique J; Varela Trastoy P; Nuñez A; Ricart E; Riestra S; Arias García L; Rodríguez M; Arranz L; Pajares R; Mena R; Calafat M; Camo P; Bermejo F; Ponferrada Á; Madrigal RE; Llaó J; Sesé E; Sánchez E; Pineda Mariño JR; González Muñoza C; Carbajo López AY; Julián AB; Villoria Ferrer A; Baston-Rey I; Jara L; Almela P; Codesido L; de la Maza S; Leal C; Caballol B; Pérez-Martínez I; Vinuesa Campo R; Crespo J; Domènech E; Chaparro M; Gisbert JP
J Crohns Colitis; 2024 Jan; 18(1):65-74. PubMed ID: 37522878
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn's disease patients over three years.
Barkai LJ; Gonczi L; Balogh F; Angyal D; Farkas K; Farkas B; Molnar T; Szamosi T; Schafer E; Golovics PA; Juhasz M; Patai A; Vincze A; Sarlos P; Farkas A; Dubravcsik Z; Toth TG; Szekely H; Miheller P; Lakatos PL; Ilias A
Sci Rep; 2024 Jun; 14(1):14909. PubMed ID: 38942890
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn's disease.
Garg R; Aggarwal M; Mohammed A; Achkar JP; Lashner B; Philpott J; Cohen B; Qazi T; Rieder F; Regueiro M; Click B
Indian J Gastroenterol; 2023 Oct; 42(5):718-723. PubMed ID: 37523059
[TBL] [Abstract][Full Text] [Related]
4. Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn's Disease: A Review of Comparative Effectiveness Studies.
Sharip MT; Nishad N; Pillay L; Goordoyel N; Goerge S; Subramanian S
J Clin Med; 2024 Apr; 13(8):. PubMed ID: 38673459
[No Abstract] [Full Text] [Related]
5. Effectiveness and safety of ustekinumab dose escalation in Crohn's disease: a multicenter observational study.
Olmedo Martín RV; Vázquez Morón JM; Martín Rodríguez MDM; Lázaro Sáez M; Hernández Martínez Á; Argüelles-Arias F
Rev Esp Enferm Dig; 2023 Dec; 115(12):686-692. PubMed ID: 37314131
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naïve or anti-TNF-exposed Crohn's disease: a multicenter cohort study.
Yang H; Huang Z; Li M; Zhang H; Fu L; Wang X; Yang Q; He Y; Wu W; Jiang T; Sun Z; Zhang T; Lai D; Wu X; Shi L; Guo Q; Wu Y; Tang J; Chao K; Gao X
EClinicalMedicine; 2023 Dec; 66():102337. PubMed ID: 38089859
[TBL] [Abstract][Full Text] [Related]
7. Biological Agents in the Treatment of Crohn's Disease: A Propensity Score-Matched Analysis From the Prospective Persistence Australian National IBD Cohort (PANIC3) Study.
Chetwood JD; Ko Y; Pudipeddi A; Kariyawasam V; Paramsothy S; Leong RW
Am J Gastroenterol; 2024 Apr; ():. PubMed ID: 38275272
[TBL] [Abstract][Full Text] [Related]
8. Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU.
Casanova MJ; Caballol B; García MJ; Mesonero F; Rubín de Célix C; Suárez-Álvarez P; Ferreiro-Iglesias R; Martín-Rodríguez MDM; de Francisco R; Varela-Trastoy P; Bastida G; Carrillo-Palau M; Núñez-Ortiz A; Ramírez-de la Piscina P; Ceballos D; Hervías-Cruz D; Muñoz-Pérez R; Velayos B; Bermejo F; Busquets D; Cabacino M; Camo-Monterde P; Marín-Jiménez I; Muñoz C; de la Peña-Negro LC; Sierra-Moros E; Barrio J; Brunet-Mas E; Bujanda L; Cañete F; Gomollón F; Manceñido-Marcos N; Rodríguez-Lago I; Rodríguez-Grau MC; Sicilia B; Torra-Alsina S; Arranz-Hernández L; Carpio D; García-Sepulcre MF; González-Muñoza C; Huguet JM; Márquez-Mosquera L; López-Serrano MP; Ponferrada-Díaz Á; Chaparro M; Gisbert JP;
Dig Liver Dis; 2024 Jun; ():. PubMed ID: 38839456
[TBL] [Abstract][Full Text] [Related]
9. Long-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID Study.
Fumery M; Caron B; Hébuterne X; Altwegg R; Roblin X; Stefanescu C; Meyer A; Nachury M; Laharie D; Le Berre C; Guillo L; Biron A; Caillo L; Buisson A; Nancey S; Uzzan M; Vuitton L; Gilletta C; Geyl S; Blain A; Kirchgesner J; Ah-Soune P; Duveau N; Vidon M; Abitbol V; Paupard T; Tran-Minh ML; Defrance A; Peyrin-Biroulet L
Clin Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38729389
[TBL] [Abstract][Full Text] [Related]
10. Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study.
Holvoet T; Truyens M; De Galan C; Peeters H; Gismero FM; Elorza A; Torres P; Vandermeulen L; Jauregui-Amezaga A; Ferreiro-Iglesias R; Zabana Y; Reverter LP; Geldof J; Lobatón T
J Clin Med; 2024 Jan; 13(2):. PubMed ID: 38256499
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of upadacitinib in Crohn's disease: a UK multicentre retrospective cohort study.
Elford AT; Bishara M; Plevris N; Gros B; Constantine-Cooke N; Goodhand J; Kennedy NA; Ahmad T; Lees CW
Frontline Gastroenterol; 2024 Jul; 15(4):297-304. PubMed ID: 38903490
[TBL] [Abstract][Full Text] [Related]
12. Importance of age, complications, progression, and risk factors in Crohn's Disease management with biologics.
Masood N; Khalid M
Dig Liver Dis; 2024 Jan; 56(1):214-215. PubMed ID: 37845153
[No Abstract] [Full Text] [Related]
13. Corrigendum to "Hypersplenism and thrombocytopenia after exposure to ustekinumab in a patient with Crohn's disease" [Arab J. Gastroenterol. 23 (2022) 288-289].
Altuwaijri MA; Aljasser MJ
Arab J Gastroenterol; 2023 Aug; 24(3):187. PubMed ID: 37679222
[No Abstract] [Full Text] [Related]
14. Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn's disease.
Yao J; Peng X; Zhong Y; Su T; Bihi A; Zhao J; Liu T; Wang W; Hu P; Zhang M; Zhi M
Front Med (Lausanne); 2023; 10():1105981. PubMed ID: 37554510
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Biological Therapies and JAK Inhibitors in Older Patients with Inflammatory Bowel Disease.
Fries W; Basile G; Bellone F; Costantino G; Viola A
Cells; 2023 Jun; 12(13):. PubMed ID: 37443755
[TBL] [Abstract][Full Text] [Related]
16. Indications and safety of newer IBD treatments in the older patient.
Clement B; De Felice K; Afzali A
Curr Gastroenterol Rep; 2023 Jul; 25(7):160-168. PubMed ID: 37227615
[TBL] [Abstract][Full Text] [Related]
17. Low-dose ganciclovir ameliorates dextran sulfate sodium-induced ulcerative colitis through inhibiting macrophage STING activation in mice.
Gong LK; Yang X; Yang J; Wu S; Chen Y; Zhang JT; Wang ZH; Chen LH; Xing C; Liu T
Front Pharmacol; 2022; 13():1020670. PubMed ID: 36467059
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of ustekinumab in elderly Crohn's disease patients.
Fiske J; Liu E; Limdi JK; Conley TE; Townsend T; Davies M; Brockwell R; Baig D; Abdelbadiee S; Uney A; Liaros A; Gaba W; Smith PJ; Flanagan PK; Subramanian S
Eur J Gastroenterol Hepatol; 2022 Nov; 34(11):1132-1139. PubMed ID: 36170682
[TBL] [Abstract][Full Text] [Related]
19. Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn's Disease Patients.
Gebeyehu GG; Fiske J; Liu E; Limdi JK; Broglio G; Selinger C; Razsanskaite V; Smith PJ; Flanagan PK; Subramanian S
Dig Dis Sci; 2023 May; 68(5):1983-1994. PubMed ID: 36436155
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
